Alan Kimelman
Pain Medicine · Vallejo, CANPI 1558474866
Payments from drug & device makers
Across 326 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Scilex Pharmaceuticals Inc.$1K
- Pfizer$603
- Takeda Pharmaceuticals U.S.A., Inc.$528
- Electronic Waveform Lab, Inc.$301
- Axsome Therapeutics, Inc.$240
- plus $945 from 12 others
What the payments were for
- Food & beverage$5,681100%
- Education$60%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 80 | $1,727 |
| Scilex Pharmaceuticals Inc. | 83 | $1,344 |
| Pfizer | 29 | $603 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $528 |
| Electronic Waveform Lab, Inc. | 20 | $301 |
| Axsome Therapeutics, Inc. | 10 | $240 |
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $233 |
| Arbor Pharmaceuticals, Inc. | 19 | $219 |
| Biohaven Pharmaceuticals, Inc. | 10 | $167 |
| Bioventus LLC | 4 | $83 |
| Supernus Pharmaceuticals, Inc. | 4 | $68 |
| Novartis | 3 | $48 |
| Avanir Pharmaceuticals, Inc. | 1 | $29 |
| Amgen | 1 | $25 |
| Upsher-smith Laboratories LLC | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| Pacira Therapeutics, Inc. | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$101
How this compares
$5,687 in reported general payments places this provider in the 70th percentile of 840 pain medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 15 | $6,973 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $3,379 |
| Atomoxetine Hcl | 12 | $1,858 |
| Vilazodone Hcl | 13 | $1,325 |
| Methylphenidate Hcl | 12 | $580 |
| Duloxetine Hcl | 29 | $303 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $267 |
| Baclofen | 26 | $241 |
| Gabapentin | 11 | $133 |
| Omeprazole | 13 | $118 |
| Prazosin Hcl | 12 | $99 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $528 | $6,97315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 840 pain medicine providers in California.
Other pain medicine in Vallejo
- Eric GrigsbyNapa$3.2M
- Jason PopeSanta Rosa$2.8M
- Javid GhandehariSanta Monica$2.7M
- Alexander HerselThousand Oaks$2.1M
- Krishnan ChakravarthyTemecula$1.9M
- Kasra AmirdelfanWalnut Creek$1.7M
- Ramana NaiduLarkspur$1.6M
- Foead GeulaStudio City$1.3M
- Xiang QianRedwood City$941K
- Jacqueline WeisbeinNapa$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.